Kelly Anderson
- Executive Director, Health and Drug Policy, Global Innovation Policy Center
Kelly Anderson is the Chamber's Senior Director of Health and Drug Policy at the Global Innovation Policy Center.
Kelly Anderson
View this online
Authored Content
The United Nations General Assembly (UNGA) will see global leaders navigate debates over IP waivers.
As leaders map out the path forward for their IP agendas, they should first consider these top findings.
Trade and innovation are both essential to U.S. prosperity — and it turns out they are closely related. Here's why America must lead on trade and innovation.
Despite the hardship of rising costs to consumers, medicines remain a stable 14% of overall health care costs.
A new report shows how a nation’s intellectual property policies influence its economic output.
For a decade, the International IP Index has helped economies better understand their unique intellectual property systems to improve and drive economic progress.
America is where innovation thrives, and cutting-edge medicine is no exception. Right now, scientists are conducting more than 140,000 clinical trials across all 50 states to explore the potential of the therapeutics, vaccines, diagnostics, and cures we need to fight disease—from coronavirus to cancer.
